2017
[IC‐01–05]: FIRST‐IN‐HUMAN PET STUDIES WITH THE NEXT GENERATION TAU AGENT 18‐F PI‐2620 IN ALZHEIMER's DISEASE, PROGRESSIVE SUPRANUCLEAR PALSY, AND CONTROLS
Barret O, Seibyl J, Stephens A, Madonia J, Alagille D, Mueller A, Berndt M, Kroth H, Capotosti F, Muhs A, Pfeifer A, Tamagnan G, Dinkelborg L, Marek K. [IC‐01–05]: FIRST‐IN‐HUMAN PET STUDIES WITH THE NEXT GENERATION TAU AGENT 18‐F PI‐2620 IN ALZHEIMER's DISEASE, PROGRESSIVE SUPRANUCLEAR PALSY, AND CONTROLS. Alzheimer's & Dementia 2017, 13: p3-p4. DOI: 10.1016/j.jalz.2017.06.2625.Peer-Reviewed Original Research
2015
Synthesis of 3‐[18F]Fluoro‐5‐(2‐Pyridinylethynyl)Benzonitrile ([18F]FPEB)
Liang S, Yokell D, Jackson R, Rice P, Livni E, Alagille D, Tamagnan G, Collier T, Vasdev N. Synthesis of 3‐[18F]Fluoro‐5‐(2‐Pyridinylethynyl)Benzonitrile ([18F]FPEB). 2015, 41-51. DOI: 10.1002/9781118834114.ch5.Peer-Reviewed Original ResearchMetabotropic glutamate receptor subtype 5Regional brain concentrationsHealthy human subjectsBrain concentrationsBrain penetranceMGluR5 antagonistSubtype 5Parkinson's diseasePathologic processesAlzheimer's diseaseNeuropsychiatric disordersNeurodegenerative diseasesDiseaseHigh potencyHuman subjectsEvidence pointsFragile X syndromeControl testsRadiochemical purityCritical roleX syndromeMGluR5SyndromeAntagonistAbnormalities
2008
P4‐346: Safety, tolerability and biomarker effects of an Abeta monoclonal antibody administered to patients with Alzheimer's disease
Siemers E, Friedrich S, Dean R, Sethuraman G, DeMattos R, Jennings D, Tamagnan G, Marek K, Seibyl J. P4‐346: Safety, tolerability and biomarker effects of an Abeta monoclonal antibody administered to patients with Alzheimer's disease. Alzheimer's & Dementia 2008, 4: t774-t774. DOI: 10.1016/j.jalz.2008.05.2416.Peer-Reviewed Original Research
2000
Measurement of alpha4beta2 nicotinic acetylcholine receptors with [123I]5-I-A-85380 SPECT.
Fujita M, Tamagnan G, Zoghbi S, Al-Tikriti M, Baldwin R, Seibyl J, Innis R. Measurement of alpha4beta2 nicotinic acetylcholine receptors with [123I]5-I-A-85380 SPECT. Journal Of Nuclear Medicine 2000, 41: 1552-60. PMID: 10994738.Peer-Reviewed Original ResearchMeSH KeywordsAlkaloidsAnimalsAzetidinesAzocinesBinding, CompetitiveBrainCerebellumImage Processing, Computer-AssistedInfusions, IntravenousInjections, IntravenousIodine RadioisotopesKineticsLeast-Squares AnalysisMagnetic Resonance ImagingPapioQuinolizinesReceptors, NicotinicThalamusTomography, Emission-Computed, Single-PhotonConceptsNicotinic acetylcholine receptorsAlpha4beta2 nAChRsAcetylcholine receptorsNew SPECT tracerAlpha4beta2 nicotinic acetylcholine receptorsPotential therapeutic roleAppropriate outcome measuresTotal distribution volumeTherapeutic roleTobacco dependenceSubcutaneous injectionBolus injectionOutcome measuresIntravenous injectionBaboon brainBolus/Alzheimer's diseaseDistribution volumeNeuropsychiatric disordersSPECT tracerCompartment modelBolus studiesInfusion ratioThalamusBolus